Deterioration of Bone Quality by Streptozotocin (STZ)-Induced Type 2 Diabetes Mellitus in Rats

Erdal, Nurten; Gürgül, Serkan; Kavak, Servet; Yıldız, Altan; Emre, Mustafa

doi:10.1007/s12011-010-8703-4

Cited by 28 publications

(25 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our results showed that BMD of the femur significantly decreased in the STZ rats, which is in agreement with a previous study [29].However, there were also some studies [30,31] that has reported no significant decrease in BMD in STZ-induced diabetic rats. We deduce that the short duration of experiment (8 weeks) in these studies may not be sufficient for the development of bone complications.…”

Section: Discussionsupporting

confidence: 93%

Pulsed electromagnetic fields inhibit bone loss in streptozotocin-induced diabetic rats

Zhou

Liao

et al. 2014

Endocrine

View full text Add to dashboard Cite

Evidences have shown that pulsed electromagnetic fields (PEMFs) can partially prevent bone loss in streptozotocin (STZ)-induced diabetic rats. However, the precise mechanisms accounting for these favorable effects are unclear. This study aimed to investigate the effects of PEMFs on bone mass and receptor activator of nuclear factor κB ligand (RANKL)/osteoprotegerin (OPG) and Wnt/β-catenin signaling pathway in STZ rats. Thirty 3-month-old Sprague Dawley rats were randomly divided into the following three groups (n = 10): control group (injection of saline vehicle), DM group (injection of STZ), and PEMFs group (injection of STZ + PEMFs exposure). One week following injection of STZ, rats in the PEMFs group were subject to PEMFs stimulus for 40 min/day, 5 days/week, and lasted for 12 weeks. After 12 week intervention, the results showed that PEMFs increased serum bone-specific alkaline phosphatase level and bone mineral density, and inhibited deterioration of bone microarchitecture and strength in STZ rats. Furthermore, PEMFs up-regulated the mRNA expressions of low-density lipoprotein receptor-related protein 5, β-catenin and runt-related gene 2 (Runx2), and down-regulated dickkopf1 in STZ rats. However, mRNA expressions of RANKL and OPG were not affected by PEMFs. PEMFs can prevent the diabetes-induced bone loss and reverse the deterioration of bone microarchitecture and strength by restoring Runx2 expression through regulation of Wnt/β-catenin signaling, regardless of its no glucose lowering effect.

show abstract

Section: Discussionsupporting

confidence: 93%

Pulsed electromagnetic fields inhibit bone loss in streptozotocin-induced diabetic rats

Zhou

Liao

et al. 2014

Endocrine

View full text Add to dashboard Cite

show abstract

“…Streptozotocin is used to induce both type I and Type II diabetes based on the dose i.e. it is concentration dependent, for the induction of type I, 60 mg/kg is given intraperitoneally or intravenously , and for type II induction 40-50mg/kg is the usual dose used 1,7,8 . In this study the rats were given an intraperitoneal injection of streptozotocin (50 mg kg−1) freshly prepared in 0.1M sodium citrate buffer.…”

Section: Induction Of Diabetesmentioning

confidence: 99%

Pharmacodynamics Drug Interactions of Metformin with Aspirin and Nifedipine

Hassan¹,

Mudawi²,

Sulaiman³

2016

AJPRHC

View full text Add to dashboard Cite

Metformin is now being recognized as the standard therapy in T2D patients who are overweight. Metformin has many drug-disease interactions that can increase the risk of metformin-associated lactic acidosis. Therefore this study was conducted to evaluate any possible pharmacodynamic interactions between metformin and drugs used to treat chronic diseases e.g. Hypertension. The rats were fasted overnight before inducing diabetes with streptozotocin. The rats were given an intraperitoneal injection of streptozotocin (50 mg kg−1) freshly prepared in 0.1M sodium citrate buffer. The diabetic state was confirmed 72 h after streptozotocin injection. Diabetic rats were grouped into seven groups each group of five rats and distributed among the normal control group diabetic control group and the treatment groups. The treatment continued for 10 days. Blood samples were taken before treatment and after 10 days and analyzed for serum glucose, cholesterol, HDL, LDL, and triglycerides. In the diabetic control group which was given STZ alone the blood glucose level decreased significantly (p < 0.05) after 10 days but still above the hyperglycemic level (200mg/dl). The same was observed in the group treated with metformin. The group treated with nifedipine and aspirin showed significant reduction (p < 0.01) in the glucose level below the hyperglycemic level (200mg/dl). While the groups treated with (Metformin + Nifedipine) and (Metformin +Aspirin) showed highly significant reduction (P<0.001) in blood glucose level. These results conclude that the combination of (metformin +Nifedipine) and the combination of (Metformin + Aspirin) have highly significant hypoglycemic effect. It also showed that Nifedipine has promising role in reducing blood glucose level, lipid profile especially LDL-cholesterol, and body weight.

show abstract

“…This is exhibited by bone loss in trabecular bone and failure to accrue cortical bone due to premature cessation of growth [14] . Further biomechanical experimental animal studies have demonstrated either increased stiffness [9,15] or reduced stiffness [16][17][18] . These variances are confusing but may be accounted for due to a number of factors.…”

mentioning

confidence: 99%

Biomechanical characteristics of bone in streptozotocin-induced diabetic rats: Anin-vivorandomized controlled experimental study

Korres

Tsiridis²,

Pavlou³

et al. 2013

WJO

View full text Add to dashboard Cite

AIM:To investigate the in vivo effects of type Ⅰ diabetes on the mechanical strength of tibial bone in a rodent model. METHODS:The biomechanical effect of diabetes on the structural integrity of the tibia in streptozotocin induced diabetic Wistar rats was analysed. Induction of diabetes was achieved by an intra-peritoneal injection and confirmed by measuring serial blood glucose levels (> 150 mg/dL). After 8 wk the tibiae were harvested and compared to a control group. Biomechanical analysis of harvested tibiae was performed using a threepoint bending technique on a servo hydraulic MTS 858 MiniBionix frame. Maximum force applied to failure (N), stiffness (N × mm) and energy absorbed (N/mm) were recorded and plotted on load displacement curves. A displacement control loading mode of 1 mm/min was selected to simulate quasi-static loading conditions. Measurements from load-displacement curves were directly compared between groups. RESULTS:Fourteen streptozotocin induced diabetic Wistar rats were compared against nineteen non-diabetic controls. An average increase of 155.2 g in body weight was observed in the control group compared with only 5 g in the diabetic group during the experimental study period. Levels of blood glucose increased to 440.25 mg/dL in the diabetic group compared to 116.62 mg/dL in the control group.The biomechanical results demonstrate a highly significant reduction in the maximum load to failure from 69.5 N to 58 N in diabetic group compared to control (P = 0.011). Energy absorption to fracture was reduced from 28.2 N in the control group to 23.5 N in the diabetic group (P = 0.082). No significant differences were observed between the groups for bending stiffness. CONCLUSION:Streptozotocin-induced diabetes in rodents reduces the maximum force and energy absorption to failure of bone, suggesting a predisposition for fracture risk.

show abstract

Deterioration of Bone Quality by Streptozotocin (STZ)-Induced Type 2 Diabetes Mellitus in Rats

Cited by 28 publications

References 43 publications

Pulsed electromagnetic fields inhibit bone loss in streptozotocin-induced diabetic rats

Pulsed electromagnetic fields inhibit bone loss in streptozotocin-induced diabetic rats

Pharmacodynamics Drug Interactions of Metformin with Aspirin and Nifedipine

Biomechanical characteristics of bone in streptozotocin-induced diabetic rats: Anin-vivorandomized controlled experimental study

Contact Info

Product

Resources

About